Celltrion Reports Positive Rheumatoid Arthritis Data From Subcutaneous Infliximab

New data presented by Celltrion at EULAR 2019 suggest that its subcutaneous formulation of infliximab is comparable to the intravenous version in treating rheumatoid arthritis.

Hands_Arthritis
Celltrion’s subcutaneous formulation of infliximab is comparable to the intravenous version in rheumatoid arthritis • Source: Shutterstock

Celltrion Healthcare’s new subcutaneous (SC) formulation of its CT-P13 biosimilar infliximab has shown positive results for the treatment of rheumatoid arthritis (RA) compared to the intravenous version, according to the firm’s latest data.

At this year’s European Congress of Rheumatology, EULAR, the South Korean firm presented a two-part study investigating the pharmacokinetics, efficacy...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.